

2026

英文論文

1. 2026 Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kudoda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Komatsu S, Tamai H, Okamura J, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishida A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Matsuura T, Noritake H, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T: Efficacy and safety of durvalumab plus tremelimumab in hepatocellular carcinoma patients with portal vein thrombosis and high tumor burden: A multicenter retrospective analysis. **Hepatol Res** 56:89-99, 2026. (IF=3.7)
2. 2026 Celsa C, Pressiani T, Nishida N, Chamseddine SM, Arvind A, Li M, Fortuny M, Khaled NB, Iavarone M, Toyoda H, Rapposelli IG, Casadei-Gardini A, Vivaldi C, Ulahannan S, Andanamala H, Scheiner B, Pinter M, Orlandi E, Fulgenzi CAM, Manfredi GF, Lombardi P, D'Alessio A, Stefanini B, Villani R, Ponziani FR, Stella L, Carminati O, Ricci AD, Gonzalez M, Di Maria ASG, Vaccaro M, Cabibbo G, Cammà C, Reig M, Kelley RK, Singal AG, Kaseb AO, **Kudo M**, Rimassa L, Pinato DJ: Reproducible safety and efficacy of durvalumab plus tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study. **JHEP Reports** 8:101685, 2026. doi.org/10.1016/j.aohep.2025.102169. (IF=8.7)
3. 2026 Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber BA, Malhotra U, Siegel AB, Liu CC, **Kudo M**, Cheng AL: Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma. **Ann Hepatol** 31:102169, 2026. (IF=6.2)
4. 2026 Nouse K, Wakuta A, Shiota S, Fujita R, Kariyama K, Hiraoka A, Atsukawa M, Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T,

2026

英文論文

- Imai M, Aoki T, Tanaka H, Hatanaka T, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Matono T, Yasuda S, Toyoda H, Iijima H, **Kudo M**, Kumada T, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Effect of butyrate-producing enterobacteria and proton pump inhibitors on advanced hepatocellular carcinoma treatment with durvalumab and tremelimumab. **JGH Open** 10:e70346, 2026. doi: 10.1002/jgh3.70346. (IF=1.6)
5. 2026 Yamao K, Takenaka M, Yoshida A, Ishikawa T, Kawashima H, **Kudo M**: Response to the letter to the editor regarding our manuscript: "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients." **Pancreatology** 26:193-194, 2026. (IF=3.9)
6. 2026 Matono T, Tada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura J, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: Lymphocyte–monocyte ratio predicts the survival in patients with HCC treated with durvalumab plus tremelimumab. **Liver Int** 46:e70570, 2026. (IF=6.2)
7. 2026 Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hanataka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H,

2026

英文論文

- Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: Three-year long-term outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab treatment in clinical practice. **Cancer Med** 15:e71640, 2026. (IF=3.5)
8. 2026 Han T, Chen L, Liu N, Han YC, Zhu Z, Wang S, Song H, Gao Z, Su L, Hu Q, Hammerich L, Pawlik TM, Zhang Y, **Kudo M**, Li H, Ma L, Valabrega G, Wang G, Yang Z, Luo Q, Marino D, Xu Z, Niu M, Chen T, Li H, Li K: Repurposed acarbose targets nidogen-1 to remodel the tumor stroma and suppress portal vein tumor thrombus in hepatocellular carcinoma. **Research** 9:1161, 2026. (IF=12.9)
9. 2026 Takenaka M, **Kudo M**: What are the future research priorities regarding biliary cannulation? How can it be mastered? What is the most crucial factor? **Digest Endosc** 38:e70093, 2026. (IF=3.6)
10. 2026 Hara A, Minaga K, Otsuka Y, Takenaka M, **Kudo M**: Rescue multihole metal stent placement to prevent stent migration after endoscopic ultrasound-guided hepaticogastrostomy. **Endoscopy** 58:E268-E269, 2026. (IF=11.8)
11. 2026 Omoto S, Takenaka M, Yoshida A, Fukunishi K, Tanaka H, Komeda Y, **Kudo M**: Full aspiration technique using a 7-Fr double-pigtail stent for endoscopic ultrasound-guided pancreatic fluid drainage of a pancreatic pseudocyst. **Endoscopy** 58:E246-E247, 2026. (IF=11.8)
12. 2026 Takenaka M, Kawamoto H, Fukunaga T, Sakano Y, Kurimoto M, Lee TH, **Kudo M**: The usefulness of the novel 0.018-inch

2026

英文論文

dedicated uneven double-lumen cannula for endoscopic ultrasound-guided hepaticogastrostomy using a 22-gauge needle. **Endoscopy** 58:E366-E367, 2026. (IF=11.8)

13. 2026 **Kudo M***: Lenvatinib as second-line regimen after atezolizumab plus bevacizumab combination therapy. **Liver Cancer** 15:1-9, 2026. (IF=10.5)
14. 2026 Vithayathil M, Manfredi GF, D'Alessio A, Fulgenzi CAM, Celsa C, Lombardi P, Torkpour A, Stefanini B, Galle PR, Nishida N, Scheiner B, Crowley F, Wu M, Ang C, Maron TU, Hsu WF, Lin CY, Lin RPT, Ulahannan S, Itani A, Soror N, Kaseb A, Lapelusa M, Schönlein M, von Felden J, Schulze K, Wege H, Wietharn B, Vivaldi C, Salani F, Masi G, Pressiani T, Dalbeni A, Natola L, Marseglia M, Piscablia F, Huang YH, Lee PC, Pirisi M, Rohlen N, Thimme R, Silletta M, Di Giacomo E, Vincenzi B, Galbato L, Vogel A, Cabibbo G, Camma C, Chon HJ, Pinter M, Cortellini A, **Kudo M**, Zanuso V, Rimassa L, Pinato DJ, Aboagye E, Sharma R: The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study. **Lancet Digit Health** 8:100952, 2026. (IF=25.5)
15. 2026 Lo Prinzi F, Rossari F, De Rosa A, Vivaldi C, **Kudo M**, Shimose S, Suda G, Camera S, Foti S, Rizzato MD, Salani F, Nishida N, Shirono T, Sakamoto N, Passeri L, Ferrara M, SoldàC, Cesario S, Ueshima K, Niizeki T, Sho T, Persano M, Vitiello F, Invernizzi F, Lonardi S, Masi G, Rimini M, Gardini AC: Efficacy and safety of lenvatinib versus sorafenib in recurrent HCC after liver transplant: A multi-center real-world study. **Hepatol Res** 56:377-386, 2026. (IF=3.7)
16. 2026 Kariyama K, Nouse K, Hiraoka A, Tada F, Ohama H, Toyoda H, Yasuda S, Tada T, Tanaka K, Tsuji K, Itobayashi E, Tsutsui A, Takaguchi K, Imai M, Ishikawa T, Hatanaka T, Kakizaki S, Naganuma A, Ueda Y, Matono T, Tamai H, Okamura J, Tanaka H,

2026

英文論文

- Yata Y, Wakuta A, **Kudo M**, Kumada T; Real-Life Practice Experts for HCC (RELPEC) Study Group: Evolution of hepatocellular carcinoma treatment outcomes over two decades in Japan: Improvements in early-stage viral disease. **Hepatol Res** 56:351-358, 2026. (IF=3.7)
17. 2026 Hiraoka A, **Kudo M**, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Toyoda H, Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouse K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T: The current status of tumor markers as biomarkers in the era of immunotherapy for hepatocellular carcinoma: alpha-fetoprotein alone is not sufficient. **Oncology** 104:79-91, 2026. (IF=1.9)
18. 2026 Lau G, Sangro B, Cheng AL, **Kudo M**, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK: Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. **Hepatology** 83:484-496, 2026. (IF=18.0)
19. 2026 Aoki T, Nishida N, **Kudo M**: Correspondence to letter to the editorial on "Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway." **Clin Mol Hepatol** 32:e241-e243, 2026. (IF=21.7)
20. 2026 Aoki T, Nishida N, **Kudo M**: Correspondence to editorial on "Molecular classification of hepatocellular carcinoma based on

2026

英文論文

- zoned metabolic feature and oncogenic signaling pathway." **Clin Mol Hepatol** 32:e79-e82, 2026. (IF=21.7)
21. 2026 Sekai I, Takita M, Yasuhara S, Omaru N, Matsubara T, Morita M, Chishina H, Minaga K, Hagiwara S, Ida H, Kojima M, Maenishi O, Watanabe T, **Kudo M**: Complete remission of acute-onset autoimmune hepatitis following transcatheter splenic arterial embolization and splenectomy for spontaneous splenic rupture. **Intern Med** 65:432-437, 2026. (IF=1.0)
22. 2026 Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, **Kudo M**, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Camma C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RPT, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schonlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ: Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. **Eur J Cancer** 240:116749, 2026. (IF=7.9)
23. 2026 Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishimura T, Nishimura T, Hanataka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Kanayama Y, Tanaka K, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Miyake T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, **Kudo M**, Hiasa Y, Kumada T: Limited Prognostic impact of sustained virologic response on atezolizumab plus bevacizumab therapy for HCV-related unresectable hepatocellular carcinoma. **Oncology** 104:487-496, 2026. (IF=1.9)

2026

英文論文

24. 2026 Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Exposito MJJ, **Kudo M**: A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). **Future Oncol** 22:1135-1152, 2026. (IF=3.1)
25. 2026 Otsuka Y, Watanabe T, **Kudo M**: A novel cancer gene therapy achieving reciprocal regulation of PTEN and PARP1 expression. **Mol Ther Oncol** 34:201194, 2026. (IF=8.5)
26. 2026 Fujihara D, Honjo H, Masuta Y, Otsuka Y, Masaki S, Minaga K, Kamata K, Tsuji N, Watanabe T, **Kudo M**: Enhanced mRNA expression of colonic IL-6 in cronkhite-Canada syndrome bearing colorectal cancer. **In Vivo** 40:1810-1817, 2026. (IF=1.8)
27. 2026 Masuta Y, Omaru N, Otsuka Y, Masaki S, Minaga K, Honjo H, Watanabe T, **Kudo M**: Methotrexate-associated systemic lymphadenopathy exhibiting a marked elevation of the serum IgG4 concentrations. **Intern Med** 65:1064-1068, 2026. (IF=1.0)
28. 2026 Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Hanataka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Tanaka H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Ueda Y, Kim SK, Tada F, Nakamura S, Matuura T, Nakamura Y, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Okamura J, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T: Efficacy and safety of atezolizumab plus bevacizumab versus durvalumab plus tremelimumab for unresectable hepatocellular carcinoma in

2026

英文論文

- patients with Child-Pugh class B: A real-world study. **Hepatol Res** 56:716-724, 2026. (IF=3.7)
29. 2026 Yopp A, Chen M, Cheng AL, Kaseb A, **Kudo M**, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PKH: Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. **J Hepatol** 84:1102-1111, 2026. (IF=40.1)
30. 2026 Yoshida S, Komeda Y, Kono M, Handa K, Nagai T, Hagiwara S, Omoto S, Takenaka M, Kashida H, Tribonias G, Daito K, Kawamura J, **Kudo M**: Diagnostic utility of endoscopic features and endoscopic UI-trasonography for ulcerative colitis-associated neoplasia: A retrospective study on the role of endoscopic submucosal dissection as a total biopsy. **Cancers** 18:1492, 2026. doi: 10.3390/cancers18091492. (IF=4.8)
31. 2026 **Kudo M***: Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC. **Liver Cancer** 15:169-177, 2026. (IF=10.5)
32. 2026 Aoki T, Tsurusaki M, Nishida N, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ueshima K, **Kudo M**: Double-balloon (CANDIS) retrograde transvenous obliteration improves hepatic functional reserve compared with the conventional method. **Intervent Radiol** 11:e20250101, 2026. (IF=0.8)
33. 2026 Otsuka Y, Minga K, Hara A, Takenaka M, Nobori C, Murase T, Matsumoto I, **Kudo M**: A rare but life-threatening complication of direct endoscopic necrosectomy: Tension pneumoperitoneum with pneumothorax and hypercapnia due to walled-off necrosis rupture. **Case Rep Gastroint Med** 6599334, 2026. (IF=0.6)
34. 2026 Yuan-Dore JSJ, Rashid M, Ueshima K, Lopes A, Ma YT, Ross P, Palmer D, **Kudo M**, Meyer T: Pattern of progression and post-

2026

英文論文

- progression survival following transarterial embolization. An analysis of the TACE-2 and TACTICS trials. **JHEP Reports** 8:101791, 2026. (IF=8.7)
35. 2026 Finn RS, **Kudo M**, Borbath I, Edeline J, Cattan S, van Vierberghe H, Verslype C, Palmer D, Stal P, Ogasawara S, Vogel A, Karwal M, Chan SL, Knox JJ, Daniele B, Odeleye-Ajakaye A, Hatogai K, Siegel AB, Cheng AL, Van Laethem JL: Pembrolizumab monotherapy in sorafenib-treated and treatment-naive advanced hepatocellular carcinoma: Long-term follow-up of open-label, phase 2 KEYNOTE-224 study. **Clin Cancer Res** 32:2007-2013, 2026. (IF=10.9)
36. 2026 Nishida N, Ueshima K, Aoki T, Matsubara T, Omaru N, Okai N, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, **Kudo M**: Impact of early-line systemic therapies on liver function in hepatocellular carcinoma: Longitudinal change of ALBI score and ammonia level with and without anti-VEGF agents. **Hepatology Res** 56:853-860, 2026. (IF=3.7)
37. 2026 Minaga K, **Kudo M**: Beyond equivalence: Reconsidering the role of EUS-guided gallbladder drainage in the post-ERCP failure algorithm. **Digest Endosc** 38:e70191, 2026. (IF=3.6)
38. 2026 Omoto S, Takenaka M, Hara A, Otsuka Y, Yoshida A, Minaga K, **Kudo M**: Half-release and full aspiration technique for endoscopic ultrasound-guided hepaticogastrostomy in severe acute cholangitis. **Endoscopy** 58:E613-E614, 2026. (IF=11.8)
39. 2026 Rimassa L, Chan SL, Sangro B, Lau G, **Kudo M**, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK: Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver

2026

英文論文

- cancer). **Future Oncol** 22:1359-1372, 2026. (IF=3.1)
40. 2026 Casadei-Gardini A, Yip TCF, Vitale A, Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Scartozzi M, Tamburini E, Foschi FG, Camera S, Persano M, D'Agata AP, Ferrara M, Passeri L, Rimassa L, Rimini M: Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. **Eur J Cancer** 240:116750, 2026. (IF=7.9)
41. 2026 Koroki K, Wakatsuki M, Ogasawara S, Makishima H, Watabe T, Anzai H, Fujiya M, Sawada M, Tsuchiya T, Katayama K, Yoshino R, Izai R, Akatsuka T, Miwa C, Yonemoto T, Yumita S, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Takahashi K, Ozawa Y, Inaba Y, Kurokawa T, Isozaki T, Takahashi A, Kato J, Ohtsuka M, Ohno T, Ueno Y, Furuse J, **Kudo M**, Hanaoka H, Ishikawa H: Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol. **BMJ Open** 16:e115731, 2026. (IF=2.5)
42. 2026 Aoki T, **Kudo M***, Ueshima K, Tsurusaki M, Sofue K, Yano Y, Toyoda H, Hiraoka A, Hatanaka T, Nakamura A, Kakizaki S, Ito K, Atsukawa M, Kawata K, Tajiri K, Tani J, Ishikawa T, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Kumada T, Nishida N, Kodama Y: Prospective study of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma based on hepatobiliary phase of Gd-EOB-DTPA-MRI. **Hepatol Res** 56:998-1006, 2026. (IF=3.7)
43. 2026 Ikeda M, **Kudo M**, Motomura K, Okusaka T, Kato N, Hisai T, Ikezawa H, Shiba S, Hoshi T, Kuroda M, Kumada H, Kobayashi M: A phase 1b study of lenvatinib plus nivolumab in patients with unresectable hepatocellular carcinoma. **Liver Cancer**, 2026 (Epub

2026

英文論文

ahead of print). (IF=10.5)

44. 2026 Matono T, Tada T, Hiraoka A, Hiroka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Ohama H, Tada F, Nakamura S, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matuura T, Ueda Y, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: L Impact of frequent immune-mediated adverse events on treatment continuity and outcomes during durvalumab plus tremelimumab therapy for unresectable hepatocellular carcinoma. **Liver Int Comm**, 2026 (Epub ahead of print). (IF=0.0)
45. 2026 Yamakawa M, Shiina T, Ito T, Akashi S, Murakami K, Watanabe T, Morishima H, Tsugawa K, Uematsu T, Nishida N, **Kudo M**: Comparison of breast ultrasound image classification accuracy between convolutional neural networks and human experts using multicenter external validation cohort data. **J Med Ultrason**, 2026 (Epub ahead of print). (IF=2.1)
46. 2026 Tada F, Hiraoka A, Ohama H, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Ueda Y, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Okamura J, Tamai H, Nakamura S, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Komatsu S, Fukumoto T, Matsuura T, Kim SK, Enomoto H, Matsui K, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC

2026

英文論文

- 48) group: Clinical characteristics, predictive factors, and the impact of antithrombotic therapy on bleeding events in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. **Hepatol Res**, 2026 (Epub ahead of print). (IF=3.7)
47. 2026 Fetzer DT, Kono Y, Piscaglia F, Dietrich CF, Meloni F, Lu Q, Clevert DA, Lyshchik A, Minami Y, Lee JM, Kim TK, Jang HJ, **Kudo M**, Wilson SR: Contrast-enhanced ultrasound L1-RADS nonradiation treatment response assessment: Applications, challenges, and future directions. **Abdom Radiol**, 2026 (Epub ahead of print). (IF=2.3)
48. 2026 Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Ueda Y, Kuroda H, Yata Y, Nishikawa H, Imai M, , Aoki T, Ochi H, Okamura J, Tamai H, Nakamura S, Nakamura T, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tada F, Ohma H, Koshiyama Y, Kanayama Y, Noritake H, Komatsu S, Fukumoto T, Matsuura T, Kim SK, Enomoto H, Matsui K, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Impact of intrahepatic tumor burden on outcomes in patients with hepatocellular carcinoma with extrahepatic metastases treated with atezolizumab plus bevacizumab. **Hepatol Res**, 2026 (Epub ahead of print). (IF=3.7)
49. 2026 **Kudo M**, Ren Z, Finn RS, Llovet JM, on behalf of the LEAP-012 investigators: Response to “Curative treatments overlooked in LEAP-012: Ethical and clinical implications for BCLC A patients” and “The LEAP-012 Trial: Quantity and quality of life considerations”. **Lancet**, 2026 (Epub ahead of print). (IF=109.0)

2026

英文論文

50. 2026 Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Ohama H, Kanayama Y, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, **Kudo M**, Hiasa Y, Kumada T, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-based tumor marker score for first-line immunotherapy selection in hepatocellular carcinoma. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
51. 2026 Masuda T, Endo Y, Kawaguchi Y, Kashiwabara K, Okamura Y, Kurosaki M, **Kudo M**, Shimada M, Yamanaka N, Yamashita T, Tateishi R, Shiina S, Fujishiro M, Matsuyama Y, Omata M, Kokudo N, Hasegawa K, Inomata M: Comparative study of laparoscopic hepatectomy, open hepatectomy, and percutaneous radiofrequency ablation for small hepatocellular carcinoma: An ancillary study of the SURF trial. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
52. 2026 Vitale A, Kim JS, Cabibbo G, Casadei-Gardini A, Iavarone M, Rimassa L, Ponziani FR, Tovoli F, Chon HJ, Kang B, Kim C, Imaoka H, Ikeda M, **Kudo M**, Aoki T, Tortora R, Guarracino M, Stefanini B, Marseglia M, Sparacino A, Celsa C, Bruccoleri M, Alimenti E, Marra F, Campani C, Bhoori S, Mazzaferro V, Sacco R, Facciorusso A, Martini A, Stella L, Cerrito L, Toyoda H, Yasuda S, Rossari F, Rimini M, Suda G, Sho T, Masi G, Vivaldi C, Pressiani T, Kakizaki S, Naganuma A, Avallone A, Nappi A, Vidili G, Soldà C, Bergamo F, Pinato DJ, Pelizzaro F, Foschi FG, Secomandi A, Verderame F, Bronte E, Martinelli E, Marino D, Grasselli S, Olivani A, Brunetto MR, Damone F, Mega A, Marzi L, Tamburini E,

2026

英文論文

- Ramundo M, Federico P, Daniele B, Giannini EG, Pasta A, Morisco F, Guarino M, Hoyek C, Boninsegna S, Gupta A, Sacerdoti D, Dalbeni A, Calvo Ramos I, Adeva J, Saitta C, Pitrone C, Lentini Graziano ML, Farella N, Rendina M, Grassi T, Rodriquenz MG, Maiello E, Presa J, Pinho I, Hiasa Y, Hirooka M, Chen J, Arrichiello G, Aschele C, Furlanetto A, Cillo U: Conversion ability of immunotherapy in hepatocellular carcinoma: Insights from the international converse study. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
53. 2026 Fujihara D, Kurimoto M, Sekai I, Otsuka Y, Masuta Y, Masaki S, Honjo H, Chikugo T, Watanabe T, **Kudo M**: Mucosa-associated lymphoid tissue lymphoma of the stomach associated with a helicobacter heilmannii sensu stricto infection one year after the successful eradication of helicobacter pylori. **Intern Med**, 2026 (Epub ahead of print). (IF=1.0)
54. 2026 Masaki S, Masuta Y, Otsuka Y, Honjo H, Watanabe T, **Kudo M**: Possible involvement of the mucosal claudin expression in the healing of a refractory ileocecal ulcer in a patient with Crohn's disease successfully treated with infliximab. **Intern Med**, 2026 (Epub ahead of print). (IF=1.0)
55. 2026 **Kudo M**^{*}, Hiraoka A, Numata K, Yamashita T, Kurosaki M, Namisaki T, Hige S, Itoh Y, Mochida S, Hosaka T, Akuta N, Kawoka T, Genda T, Kobayashi S, Kato N, Uchida S, Lu Y, Exposito MJJ, Ogata T, Ikeda M: Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for Japanese patients with unresectable hepatocellular carcinoma: Checkmate 9DW. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
56. 2026 Chan SL, **Kudo M**, Sangro B, Kelley RK, Kim JH, Pham B, Hong JY, Waldschmidt DT, Marino D, Lee JXJ, Gerolami R, Burgoyne AM, Li Q, Nakamura H, Sun P, Baur B, Rimassa L: Early safety results from the Phase 3b SIERRA study of durvalumab and tremelimumab as first-line treatment for participants with

2026

英文論文

unresectable hepatocellular carcinoma and a poor prognosis.

Liver Cancer, 2026 (Epub ahead of print). (IF=10.5)

57. 2026 Singal AG, Toyoda H, Tanwandee T, Tangkijvanich P, Tan CK, Cua IH, Alcantara-Piyawal D, Su TH, Huy NDS, Yamada H, **Kudo M**: Utility of biomarker panels in the surveillance and monitoring of hepatocellular carcinoma: Consensus statements from an international delphi panel. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
58. 2026 Kariyama K, Nouse K, Hiraoka A, Tada F, Ohama H, Toyoda H, Yasuda S, Tada T, Tanaka K, Tsuji K, Itobayashi E, Tsutsui A, Takaguchi K, Imai M, Ishikawa T, Hatanaka T, Kanayama Y, Kakizaki S, Naganuma A, Ueda Y, Matono T, Tamai H, Okamura J, Tanaka H, Yata Y, Wakuta A, **Kudo M**, Kumada T: Ablation-based salvage strategy at disease progression after initial disease control with atezolizumab/bevacizumab in hepatocellular carcinoma. **Hepatol Res**, 2026 (Epub ahead of print). (IF=3.7)
59. 2026 Aoe K, Tada T, Hiraoka A, Matono T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura J, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T: Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study. **Hepatology**, 2026 (Epub ahead of print). (IF=18.0)
60. 2026 Mahipal A, Cheng AL, **Kudo M**, Burgoyne A, Kalyan A, Lencioni R, Lopéz CL, Daniele B, Palmer DH, Baron AD, Park JW, Ren M, Mody K, Vogel A: Characterization of patients with unresectable

2026

英文論文

hepatocellular carcinoma in REFLECT who achieved tumor response or alpha-fetoprotein response when treated with Lenvatinib. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)

61. 2026 Aoki T, **Kudo M**, Ogiso S, Okumura G, Hoshino M, Nakamura Y, Morisue R, Koyama S, Nishida N, Hanaoka K, Sakai K, Kurebayashi Y, Tsurusaki M, Morita M, Takebe A, Murase T, Kamei K, Matsumoto I, Nishio K, Nishikawa H, Hatano E: Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
62. 2026 Kim JS, Chen SC, Wong JSL, Kang B, Lim HY, Kim I, Kim H, An C, Jang SJ, **Kudo M**, Tai D, Kim C, Yau T, Chon HJ: Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: An International multicenter study. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
63. 2026 Matono T, Tada T, Hiraoka A, Hirooka M, Nakamura Y, Yoshida O, Kariyama K, Nouse K, Tani J, Morishita A, Atsukawa M, Itokawa N, Okubo T, Arai T, Takaguchi K, Tsutsui A, Nagano T, Itobayashi E, Nishimura T, Fukunishi S, Enomoto H, Tsuji K, Tanaka K, Ishikawa T, Imai M, Tajiri K, Tanaka H, Toyoda H, Koshiyama Y, Ogawa C, Hatanaka T, Kanayama Y, Kakizaki S, Kawata K, Noritake H, Naganuma A, Kosaka H, Matsui K, Kaibori M, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Okamura J, Komatsu S, Matsuura T, Nakamura S, Ueda Y, Kim SK, Ohama H, Tada F, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: Outcomes of patients with hepatocellular carcinoma treated with durvalumab plus tremelimumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 HIMALAYA trial. **J Gastroenterol Hepatol**, 2026 (Epub ahead of print). (IF=3.5)
64. 2026 Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Tsuji K, Ishikawa T, Tajiri

2026

英文論文

- K, Tanaka H, Toyoda H, Ogawa C, Hanataka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura H, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T: Real-world comparison of first-line atezolizumab plus bevacizumab and durvalumab plus tremelimumab for unresectable hepatocellular carcinoma. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
65. 2026 **Kudo M***: The China paradox in LEAP-012 trial. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)
66. 2026 Terashima T, Ikeda M, Yamashita T, Okusaka T, Imaoka H, Kawaoka T, Kobayashi S, Ogasawara S, Hiraoka A, Nakano M, Okano N, Sugimoto R, Moriguchi M, Inaba Y, Shinoda S, Ueno M, **Kudo M**, Furuse J, Nagano H: A multicenter phase II study on atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh classification B cirrhosis: CHALLENGE trial. **Liver Cancer**, 2026 (Epub ahead of print). (IF=10.5)